Simple Moving Average Analysis of Boston Scientific Corporation (BSX)

Cornelia Mascio
Mag 17, 2018

Perhaps, that suggests something about why 0.86% of the outstanding share supply is held by institutional investors.

Argent Capital Management Llc decreased its stake in Boston Scientific Corporation (BSX) by 32.57% based on its latest 2017Q4 regulatory filing with the SEC. Moving average strategies are also popular and can be tailored to any time frame, suiting both long term investors and short-term traders. Investors mark this stock "active" as it exchanged hands with 267,445 shares contrast to its average daily volume of 1.75M shares. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its holdings in Boston Scientific by 61.4% during the fourth quarter. Vontobel Asset Management Inc. now owns 1,651,580 shares of the medical equipment provider's stock worth $40,945,000 after purchasing an additional 266,067 shares during the last quarter. First Personal Financial Services grew its holdings in Boston Scientific by 42.9% during the fourth quarter. First Personal Financial Services now owns 13,015 shares of the medical equipment provider's stock valued at $323,000 after buying an additional 3,908 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its holdings in shares of Boston Scientific by 4.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 7,149,847 shares of the medical equipment provider's stock valued at $177,245,000 after buying an additional 5,633,721 shares in the last quarter.

In latest trading activity; Boston Scientific Corporation (BSX) snatched the consideration from Investors, when its current damaging picture was seen that is promoting bad performance.

Shares of Boston Scientific opened at $29.62 on Wednesday, MarketBeat reports. Its quick ratio for the most recent quarter is 0.60. Boston Scientific has a twelve month low of $28.49 and a twelve month high of $30.35.

Trading at the moment with a market cap of $37.82B, EBAY has a significant cash 2.53 billion on their books, which will have to be weighed and compared to their $2.57 billion in total current liabilities. Finally, Morgan Stanley upped their price target on Boston Scientific from $30.00 to $33.00 and gave the company an overweight rating in a report on Monday, March 19th. The medical equipment provider reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.01. Boston Scientific had a return on equity of 25.10% and a net margin of 1.21%. That value represents a market adjusting for revenues that have been growing by 10.14 % on a quarterly year/year basis as of the company's last quarterly report. During the same period last year, the firm earned $0.29 EPS. analysts expect that Boston Scientific will post 1.39 EPS for the current fiscal year.

In other Boston Scientific news, SVP David A. Pierce sold 5,152 shares of the stock in a transaction dated Thursday, February 1st. Research analysts often publish stock price targets along with buy-sell recommendations. The sale was disclosed in a document filed with the SEC, which is available through this link. The stock was sold at an average price of $27.00, for a total transaction of $439,722.00. The disclosure for this sale can be found here. We observed 3.70% rate of return for a stock for the last 5-trading days, which was maintained for the month at -5.74%.

Analysts have a mean rating score of 1.7 on this stock. Checking on the stock price, we can see that a recent tick has seen company shares hitting 35.66. Jefferies Group reiterated a "hold" rating and issued a $31.00 price objective on shares of Boston Scientific in a research report on Thursday, April 26th. The higher the RVOL the more In Play the stock is. 1 is equivalent to a buy rating, 3 a hold rating, and 5 a sell rating. In Wednesday, April 25 report Stifel Nicolaus maintained it with "Buy" rating and $3300 target. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, fourteen have issued a buy rating and three have assigned a strong buy rating to the stock. The consensus recommendation is the average rating on a stock by the analyst community.

Boston Scientific Corporation (BSX) is an interesting player in the Healthcare space, with a focus on Medical Appliances & Equipment. It operates through three divisions: Cardiovascular, Rhythm Management, and MedSurg.The P/E ratio is 388.55. The firm offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE